A Network Meta-Analysis Comparing Effects of Various Antidepressant Classes on the Digit Symbol Substitution Test (DSST) as a Measure of Cognitive Dysfunction in Patients with Major Depressive Disorder
暂无分享,去创建一个
[1] J. Jaeger,et al. P.1.j.033 The digit symbol substitution test (DSST): psychometric properties and clinical utility in major depressive disorder , 2016, European Neuropsychopharmacology.
[2] R. McIntyre,et al. The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials , 2016, The international journal of neuropsychopharmacology.
[3] B. Baune,et al. A review on the impact of cognitive dysfunction on social, occupational, and general functional outcomes in bipolar disorder , 2015, Bipolar disorders.
[4] R. McIntyre,et al. The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials , 2015, The international journal of neuropsychopharmacology.
[5] G. Papakostas,et al. Understanding and managing Cognition in the Depressed Patient. , 2015, The Journal of clinical psychiatry.
[6] C. Sánchez,et al. Treatment of cognitive dysfunction in major depressive disorder--a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine. , 2015, European journal of pharmacology.
[7] J. Zajecka,et al. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder , 2015, Neuropsychopharmacology.
[8] S. Nasr,et al. Prescriber's Guide to Using 3 New Antidepressants: Vilazodone, Levomilnacipran, Vortioxetine , 2015 .
[9] B. Baune,et al. Pharmacological and non-pharmacological interventions to improve cognitive dysfunction and functional ability in clinical depression – A systematic review , 2014, Psychiatry Research.
[10] Charles R. Yang,et al. Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in the rat hippocampus , 2014, Journal of psychopharmacology.
[11] P. Doraiswamy,et al. Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review. , 2014, The Journal of clinical psychiatry.
[12] D. Morilak,et al. Vortioxetine restores reversal learning impaired by 5-HT depletion or chronic intermittent cold stress in rats , 2014, The international journal of neuropsychopharmacology.
[13] R. McIntyre,et al. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults , 2014, The international journal of neuropsychopharmacology.
[14] M. Phillips,et al. Amygdala and whole‐brain activity to emotional faces distinguishes major depressive disorder and bipolar disorder , 2013, Bipolar disorders.
[15] G. Freedman,et al. Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010 , 2013, PLoS medicine.
[16] J. Roiser,et al. Cognitive impairment in depression: a systematic review and meta-analysis , 2013, Psychological Medicine.
[17] P. Celada,et al. P.2.e.003 Role of 5-HT3 receptors in the mechanism of action of the investigational antidepressant vortioxetine , 2013, European Neuropsychopharmacology.
[18] B. Baune,et al. Short- and long-term relationships between neurocognitive performance and general function in bipolar disorder , 2013, Journal of clinical and experimental neuropsychology.
[19] Janet B W Williams. Diagnostic and Statistical Manual of Mental Disorders , 2013 .
[20] R. Lee,et al. A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder. , 2012, Journal of affective disorders.
[21] C. Sánchez,et al. P.2.h.002 Effects of the multimodal antidepressant Lu AA21004 on rat synaptic and cellular hippocampal plasticity and memory recognition , 2012, European Neuropsychopharmacology.
[22] Cornelius Katona,et al. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder , 2012, International clinical psychopharmacology.
[23] Michael F. Green,et al. The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? , 2011, Schizophrenia bulletin.
[24] E. Walker,et al. Diagnostic and Statistical Manual of Mental Disorders , 2013 .
[25] B. Baune,et al. Specifying the Neuropsychology of Affective Disorders: Clinical, Demographic and Neurobiological Factors , 2011, Neuropsychology Review.
[26] P. de Jonge,et al. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study , 2010, Psychological Medicine.
[27] B. Baune,et al. The role of cognitive impairment in general functioning in major depression , 2010, Psychiatry Research.
[28] A. Rush,et al. Health-related quality of life in depression: a STAR*D report. , 2010, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.
[29] Donatella Marazziti,et al. Cognitive impairment in major depression. , 2010, European journal of pharmacology.
[30] Å. Hammar,et al. Cognitive Functioning in Major Depression – A Summary , 2009, Front. Hum. Neurosci..
[31] G. Kaprinis,et al. Prediction and prevention of suicide in patients with unipolar depression and anxiety , 2007, Annals of general psychiatry.
[32] R. Porter,et al. Neuropsychological Impairment in Major Depression: Its Nature, Origin and Clinical Significance , 2007, The Australian and New Zealand journal of psychiatry.
[33] C. Mathers,et al. Projections of Global Mortality and Burden of Disease from 2002 to 2030 , 2006, PLoS medicine.
[34] G. Turecki,et al. Suicide Cases in New Brunswick from April 2002 to May 2003: The Importance of Better Recognizing Substance and Mood Disorder Comorbidity , 2006, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[35] K. Hugdahl,et al. Neuropsychological test profiles in schizophrenia and non‐psychotic depression , 2006, Acta psychiatrica Scandinavica.
[36] J. Tignol,et al. Double‐blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major dipressive episode , 1998 .
[37] M. Boyle,et al. P-12-35 Utility-based measures of health-related quality of life in depression , 1996, European Neuropsychopharmacology.
[38] F. Artigas,et al. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. , 2015, Pharmacology & therapeutics.
[39] A. Carvalho,et al. The impact of cognitive impairment on perceived workforce performance: results from the International Mood Disorders Collaborative Project. , 2015, Comprehensive psychiatry.
[40] B. Mulsant,et al. The MMSE is not an adequate screening cognitive instrument in studies of late-life depression. , 2009, Journal of psychiatric research.
[41] J. Tignol,et al. Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode. , 1998, Acta psychiatrica Scandinavica.